Patents by Inventor Xiaomei Ren

Xiaomei Ren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10683278
    Abstract: Provided are a substituted quinolone derivative as shown by formula (I), or a pharmaceutically acceptable salt and a prodrug molecule thereof, and a pharmaceutical composition thereof, as well as the use of same in preparing drugs for the prevention and treatment of a tumor. The quinolone derivative, salt, prodrug molecule, and pharmaceutical composition thereof can be used as a protein kinase inhibitor, which is effective in inhibiting the activity of AXL protein kinase, and is capable of inhibiting the proliferation, migration and invasion of various tumor cells; and can be used in the preparation of anti-tumor drugs, especially drugs for treating hyperproliferative diseases such as a tumor in human beings and other mammals.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: June 16, 2020
    Assignees: SHANGHAI HAIHE PHARMACEUTICAL CO., LTD., JINAN UNIVERSITY, SHANGHAI INTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Ke Ding, Meiyu Geng, Li Tan, Jian Ding, Zhang Zhang, Jing Ai, Xiaomei Ren, Donglin Gao, Zhengchao Tu, Xiaoyun Lu, Dongmei Zhang
  • Publication number: 20200017491
    Abstract: Fibroblast Growth Factor Receptor kinase inhibitors and prodrugs thereof of Formula (I) and their use for the treatment of hyper-proliferative diseases such as retinopathy, psoriasis, rheumatoid arthritis, osteoarthritis, septic arthritis, tumour metastasis, periodontal disease, corral ulceration, proteinuria, coronary thrombosis from atherosclerotic plaque, aneurismal aorta, dystrophobic epidermolysis bullosa, degenerative cartilage loss following traumatic joint injury, osteopenias mediated by MMP activity, tempero mandibular joint disease, and demyelating disease of the nervous system.
    Type: Application
    Filed: March 2, 2018
    Publication date: January 16, 2020
    Applicants: Auckland Uniservices Limited, Guangzhou Intitute of BioMedicine and Health
    Inventors: Adam Vorn PATTERSON, Jeffrey Bruce SMAILL, Amir ASHOORZADEH, Christopher Paul GUISE, Christopher John SQUIRE, Swarnalatha Akuratiya GAMAGE, Maria Rosaria ABBATTISTA, Matthew Roy BULL, Angus Cheverton GREY, Xueqiang LI, Ke DING, Xiaomei REN, Shuang JIANG, Zhengchao TU
  • Publication number: 20200002552
    Abstract: An intumescent coating system contains: a polyol component; an isocyanate component; a latent crosslinker having two or more —NACH2OR groups, where A is selected from a group consisting of H and —CH2OR, and in each case R is independently selected from a group consisting of hydrocarbons having from one to four carbons, the latent crosslinker being present at a concentration of 30 weight-percent or more based on polyol weight; a boron component one weight-percent or more and 10 weight-percent or less based on total weight of the formulation; and expandable graphite at a concentration of 10 weight-percent or more and 50 weight-percent or less based on the total intumescent system weight; where the polyol and isocyanate are selected so that the reaction product at room temperature of the intumescent coating system components produces a coating having a tensile elongation of 40-percent or more as determined according to ISO 37.
    Type: Application
    Filed: March 14, 2017
    Publication date: January 2, 2020
    Inventors: Xiaomei Song, Dakai Ren, Hongyu Chen, Yi Zhang
  • Patent number: 10370360
    Abstract: Compounds of formula (I), their pharmaceutically acceptable salts and stereoisomers thereof, as well as application in effectively inhibiting the enzymatic activity of discoidin domain receptor 1 and can be used as new therapeutic agents for preventing and treating e.g. inflammation, liver fibrosis, kidney fibrosis, lung fibrosis, skin scar, atherosclerosis, and cancer. The compound of formula I is: wherein the variables are as defined herein.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: August 6, 2019
    Assignees: The Board of Regents of the University of Texas System, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
    Inventors: Rolf A. Brekken, Ke Ding, Xiaomei Ren, Zhengchao Tu, Zhen Wang, Kristina Y. Aguilera
  • Publication number: 20180265496
    Abstract: Provided are a substituted quinolone derivative as shown by formula (I), or a pharmaceutically acceptable salt and a prodrug molecule thereof, and a pharmaceutical composition thereof, as well as the use of same in preparing drugs for the prevention and treatment of a tumor. The quinolone derivative, salt, prodrug molecule, and pharmaceutical composition thereof can be used as a protein kinase inhibitor, which is effective in inhibiting the activity of AXL protein kinase, and is capable of inhibiting the proliferation, migration and invasion of various tumor cells; and can be used in the preparation of anti-tumor drugs, especially drugs for treating hyperproliferative diseases such as a tumor in human beings and other mammals.
    Type: Application
    Filed: August 18, 2016
    Publication date: September 20, 2018
    Applicants: JINAN UNIVERSITY, SHANGHAI INSTITUTE OF MATERIA MEDICA,CHINESE ACADEMY OF SCIENCES
    Inventors: Ke DING, Meiyu GENG, Li TAN, Jian DING, Zhang ZHANG, Jing AI, Xiaomei REN, Donglin GAO, Zhengchao TU, Xiaoyun LU, Dongmei ZHANG
  • Patent number: 10059694
    Abstract: Disclosed are a 2-aminopyrimidine compound and pharmaceutical composition and use thereof. The structure of the 2-aminopyrimidine compound is as represented by formula I, in the formula, R1, R2, R3, R4, R5, X, Y, Z, W, (i) being as defined in the specification and the claims. Such compounds effectively inhibit the growth of a variety of tumor cells and have inhibitory effects on EGFR and IGF1R protease, and can be used for preparing antineoplastic drugs and overcome the tolerance induced by the existing drugs such as gefitinib, erlotinib and the like. The compound has selectivity for tumors, in particular the wild-type non-small cell lung cancer and have good pharmacokinetic characteristics.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: August 28, 2018
    Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES
    Inventors: Ke Ding, Jian Ding, Shingpan Chan, Meiyu Geng, Xiaomei Ren, Hua Xie, Zhengchao Tu, Yi Chen
  • Publication number: 20180022730
    Abstract: Compounds of formula (I), their pharmaceutically acceptable salts and stereoisomers thereof, as well as application in effectively inhibiting the enzymatic activity of discoidin domain receptor 1 and can be used as new therapeutic agents for preventing and treating e.g. inflammation, liver fibrosis, kidney fibrosis, lung fibrosis, skin scar, atherosclerosis, and cancer. The compound of formula I is: wherein the variables are as defined herein.
    Type: Application
    Filed: October 21, 2015
    Publication date: January 25, 2018
    Inventors: Rolf A. BREKKEN, Ke DING, Xiaomei REN, Zhengchao TU, Zhen WANG, Kristina Y. AGUILERA
  • Publication number: 20170283398
    Abstract: Disclosed are a 2-aminopyrimidine compound and pharmaceutical composition and use thereof. The structure of the 2-aminopyrimidine compound is as represented by formula I, in the formula, R1, R2, R3, R4, R5, X, Y, Z, W, (i) being as defined in the specification and the claims. Such compounds effectively inhibit the growth of a variety of tumor cells and have inhibitory effects on EGFR and IGF1R protease, and can be used for preparing antineoplastic drugs and overcome the tolerance induced by the existing drugs such as gefitinib, erlotinib and the like. The compound has selectivity for tumors, in particular the wild-type non-small cell lung cancer and have good pharmacokinetic characteristics.
    Type: Application
    Filed: November 18, 2015
    Publication date: October 5, 2017
    Applicants: Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES
    Inventors: Ke Ding, Jian Ding, Shingpan Chan, Meiyu Geng, Xiaomei Ren, Hua Xie, Zhengchao Tu, Yi Chen